Global Huntington’s Disease Drugs Market Forecast 2018-2028
Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules
• Do you need definitive Huntington’s Disease market data? • Succinct Huntington’s Disease market analysis? • Technological insight? • Actionable business recommendations?
Read on to discover how this definitive report can transform your own research and save you time.
The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines. Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
Report highlights • 77 quantitative tables, charts, and graphs across 163 pages
• Global Huntington’s Disease market outlook and analysis from 2018-2028
• Global Huntington’s Disease submarket forecasts and analysis from 2018-2028 • Antidopaminergics • Antipsychotics • Anticonvulsants • Antidepressants • Other
• Regional and National Huntington’s Disease market forecasts 2018-2028 • North America forecast 2018-2028 • US forecast 2018-2028 • Rest of North America forecast 2018-2028
• Europe forecast 2018-2028 • Germany forecast 2018-2028 • UK forecast 2018-2028 • France forecast 2018-2028 • Italy forecast 2018-2028 • Spain forecast 2018-2028 • Rest of Europe forecast 2018-2028
• Rest of World forecast 2018-2028
Key questions answered • What does the future hold for the Pharmaceutical industry with regards to Huntington’s Disease • Where should you target your business strategy? • Which applications should you focus upon? • Which disruptive technologies should you invest in? • Which companies should you form strategic alliances with? • Which company is likely to success and why? • What business models should you adopt? • What industry trends should you be aware of?
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Why You Should Read This Report 1.2 How This Report Delivers 1.3 Key Questions Answered by This Analytical Report Include: 1.4 Who is This Report For? 1.5 Methodology 1.5.1 Primary Research 1.5.2 Secondary Research 1.5.3 Market Evaluation & Forecasting Methodology 1.6 Frequently Asked Questions (FAQ) 1.7 Associated Visiongain Reports 1.8 About Visiongain
2. Introduction to Huntington’s Disease 2.1 What Are the Causes And Risk Factors Of Huntington’s Disease? 2.1.1 Risk Factors 2.1.1.1 Alcohol Intake 2.1.1.2 Pneumonia: 2.1.1.3 Stress 2.2 Symptoms of Huntington’s Disease 2.2.1 Symptoms in Adult Onset 2.2.2 Movement Disorders 2.2.3 Cognitive Disorders 2.2.4 Psychiatric Disorders 2.2.5 Symptoms in Juvenile Onset 2.2.6 Behavioural Changes: 2.3 Diagnosis of Huntington’s Disease 2.3.1 Neurological Tests: 2.3.2 Brain Function and Imaging Tests: 2.3.3 Genetic Testing: 2.3.4 Psychiatric Tests: 2.3.5 Test in Pregnancy: 2.3.6 Preimplantation Genetic Diagnosis: 2.4 Treatment of Huntington’s Disease 2.4.1 Medications for Movement Disorders: 2.4.2 Medications for Psychiatric Disorders: 2.4.3 Psychotherapy 2.4.4 Speech Therapy 2.4.5 Physical Therapy 2.4.6 Occupational Therapy 2.5 Epidemiology of Huntington’s Disease 2.6 Social and Economic Burden 2.6.1 Mortality 2.6.2 Morbidity 2.6.3 Economic Impact 2.7 Introduction to the Global Huntington’s Disease Market
3. Global Huntington’s Disease Market Size And Forecast By Drug Class 3.1 Market Segmentation by Application 3.2 Global Antidopaminergics Market 3.2.1 Market Overview 3.2.2 Market Size and Forecast 3.3 Global Antipsychotics Market 3.3.1 Market Overview 3.3.2 Market Size and Forecast 3.4 Global Anticonvulsants Market 3.4.1 Market Overview 3.4.2 Market Size and Forecast 3.5 Global Antidepressants Market 3.5.1 Market Overview 3.5.2 Market Size and Forecast 3.6 Global Other Huntington’s Disease Drugs Market 3.6.1 Market Overview 3.6.2 Market Size and Forecast
4. Leading Drugs in Global Huntington’s Disease Market, 2017 4.1 Xenazine (tetrabenazine) 4.2 Austedo (Deutetrabenazine) 4.3 Clozapine 4.4 Haloperidol 4.5 Abilify 4.6 Risperdal
5. Leading National Markets Forecast 2017-2028 5.1 Geographical Breakdown of Global Huntington’s Disease Drugs Market, 2016 5.2 Huntington’s Disease Drugs Market in the Americas, 2016 5.3 Huntington’s Disease Drugs Market in the EU5, 2016 5.3.1 Market Forecast of the EU5 Countries, 2017-2028 5.3.2 The UK 5.3.3 Germany 5.3.4 France 5.3.5 Spain 5.3.6 Italy 5.3.7 Huntington’s Disease Drugs Market in the Rest of Europe, 2016 5.4 Huntington’s Disease Drugs Market in the Rest of the World, 2016 5.4.1 Japan 5.4.2 China 5.4.3 Russia
6. Qualitative Analysis of the Huntington’s Disease Market 6.1 Market Growth Drivers 6.1.1 Unmet Medical Need 6.1.2 Special Regulatory Provisions for Rare Diseases 6.1.3 Designated ICD-10 Code 6.1.4 Increased investment in R&D 6.1.5 Alternative Therapies 6.2 Market Challenges 6.2.1 Poor Diagnosis Rates 6.2.2 Limited Patient Population 6.2.3 Stringent Regulatory Guidelines 6.2.4 Alternative programs for management of mental disorders 6.3 Market Trends 6.3.1 Advances in Biomedical Sciences 6.3.2 Focus on Regenerative Therapies for Mental Disorders 6.3.3 Rising Public Interest Toward Mental Health 6.3.4 Novel Mechanisms Targeted by Pipeline Candidates 6.3.5 Emergence of First-in-class Pipeline Molecules
8. Leading Companies in Global Huntington’s Disease Market, 2017 8.1 Hoffmann-La Roche Ltd. 8.1.1 SWOT Analysis: 8.2 H. Lundbeck 8.2.1 Business Strategy: 8.2.2 SWOT Analysis: 8.3 Teva Pharmaceutical Industries Ltd. 8.3.1 Business Strategy: 8.3.2 SWOT Analysis: 8.4 Prana Biotechnology 8.5 Sangamo Therapeutics Inc. 8.6 Horizon Pharma Plc. 8.6.1 Revenue from Business Units: 8.6.2 Business Strategy: 8.6.2.1 Key Developments: 8.6.2.2 SWOT Analysis: 8.7 Omeros Corp. 8.7.1 SWOT Analysis: 8.8 Valeant Pharmaceuticals International Inc. 8.8.1 Business strategy: 8.8.2 SWOT Analysis
9. Executive Summary and Recommendations
10. Glossary Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 1.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share) Figure 2.1 Example of Huntington's Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share) Figure 2.2 Global Huntington's Disease Market Segmentation by Drug Class (% Share) Figure 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 3.2 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 3.3 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 3.4 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 3.5 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 3.6 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%) Figure 5.1 Global Huntington's Disease Drugs Market Segmentation by Region/Country Figure 5.2 Global Huntington's Disease Drugs Market by Region: Revenue ($m) Figure 5.3 Global Huntington's Disease Drugs Market by Region: Market Share 2016 (%) Figure 5.4 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%) Figure 5.5 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%) Figure 5.6 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017 (%) Figure 5.7 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2022 (%) Figure 5.8 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2027 (%) Figure 5.9 Huntington's Disease Drugs Market in the US: 2016 Market Share % Figure 5.10 Huntington's Disease Drugs Market in the US: 2016 Revenue ($m), Market Share % Figure 5.11 Huntington's Disease Market Forecast in the US 2017-2028: Revenue ($m), AGR (%) Figure 5.12 Huntington's Disease Drugs Market in the EU5 2016: Global Market Share (%) Figure 5.13 Huntington's Disease Drugs Market in the EU5 Countries 2016: Market Share (%) Figure 5.14 Huntington's Disease Drugs Market in the EU5 Countries 2028 Market Share (%) Figure 5.15 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2017-2028 Figure 5.16 Global Huntington's Disease Drugs Market Forecast in The UK 2017-2028: Revenue ($m), AGR (%) Figure 5.17 Global Huntington's Disease Drugs Market Forecast in Germany 2017-2028: Revenue ($m), AGR (%) Figure 5.18 Global Huntington's Disease Drugs Market Forecast in France 2017-2028: Revenue ($m), AGR (%) Figure 5.19 Global Huntington's Disease Drugs Market Forecast in Spain 2017-2028: Revenue ($m), AGR (%) Figure 5.20 Global Huntington's Disease Drugs Market Forecast in Italy 2017-2028: Revenue ($m), AGR (%) Figure 5.21 Huntington's Disease Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2017-2028 Figure 5.22 Huntington's Disease Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2017-2028 Figure 8.1: Roche: Sales 2016 Figure 8.2: Roche: Sales 2016 Figure 8.3: H. Lundbeck: SWOT Analysis 2016 Figure 8.4 Teva: SWOT Analysis 2016 Figure 8.5 Horizon Revenue by Business Unit Figure 8.6 Horizon: Drugs under Orphan Business Unit: Figure 8.7 Horizon Drugs under Primary Care Unit: Figure 8.8 Horizon: Drugs under Rheumatology Business Unit: Figure 8.9 Horizon SWOT Analysis Figure 8.10 Omeros Corp: SWOT Analysis Figure 8.11 Valeant SWOT Analysis Figure 9.1 Global Huntington's Disease Market Forecast 2017-2028: Revenue ($m), AGR (%)
List of Tables Table 1.1 Example of Huntington's Disease Market by Regional Market Forecast 2017-2028 (US$m, AGR %, Cumulative) Table 2.1: Prevalence of Huntington's Disease by Geography 2015 Table 2.2: Incidence of Huntington's Disease by Geography 2015 Table 3.1 Global Huntington's Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 3.2 Global Antidopaminergics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 3.3 Global Antipsychotics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 3.4 Global Anticonvulsants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 3.5 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 3.6 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) Table 5.1 Global Huntington's Disease Drugs Market by Region: Revenue ($m), and Market Share (%), 2016 Table 5.2 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028 Table 5.3 Global Huntington's Disease Drugs Market by Region: AGR 2017-2028 (%) Table 5.4 Global Huntington's Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%) Table 5.7 Global Huntington's Disease Drugs Market Forecast in the Americas: Revenue ($m), AGR (%), CAGR (%),2017-2028 Table 5.8 Global Huntington's Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028 Table 5.9 Huntington's Disease Drugs Market in the EU5, 2017 Table 5.10 Huntington's Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.11 Huntington's Disease Drugs Market Forecast in UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.12 Huntington's Disease Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.13 Huntington's Disease Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.14 Huntington's Disease Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.15 Huntington's Disease Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.16 Huntington's Disease Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 5.17 Huntington's Disease Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2017-2028 Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease Table 7.1: Active Pipeline Molecules under Development for Treating Huntington's Disease (Continued) Table 8.1:Roche: Overview 2016 Table 8.2: H. Lundbeck: Overview 2016 Table 8.3: Teva: Overview 2016 Table 8.4 Prana: Overview 2016 Table 8.5: Sangamo: Overview 2016 Table 8.6: Horizon: Overview 2016 Table 8.7: Omeros: Overview 2016 Table 8.8: Valeant: Overview 2016
Abbott Laboratories,Inc., Actavis Aldagen Allergan, Inc Astra Zeneca Auspex Pharmaceuticals Inc Australian Securities Exchange Bausch + Lomb Baxter International, Inc. BioMarin Boston Scientific Corporation BrainCells Bristol-Meyers Squibb Cardinal Health Cephalon Inc. CHDI Foundation Defined Health Dow AgroSciences Eli Lilly F. Hoffmann-La Roche AG Fate Therapeutics Forest Laboratories Gedeon Richter Genzyme Germany Effects Glaxo SmithKline H. Lundbeck Horizon Pharmaceutical LLC. Hospira, Inc InterMune Intra-Cellular Therapies Ionis Pharmaceuticals Isis Pharmaceuticals iZumi Bio. Janssen Pharmaceuticals Johnson & Johnson KDL Lundbeck Pharmaceuticals Lupin Luye Pharma Marnac Medtronic, Inc. Merck Serono MSI Methylation Sciences Mylan Pharmaceuticals Naurex Neuroptix Corporation Novartis AG Omeros Corporation Opko Health Otsuka America Pharmaceutical, Inc. Otsuka Pharmaceutical Ovation Pharmaceuticals Pfizer, Inc. Prana Biotechnology Raptor Pharmaceuticals River Vision Development Corp Sangamo BioSciences, Inc Sangamo Therapeutics Sanofi Shionogi Seiyaku Shire plc Sigma-Aldrich Corporation SK Biopharmaceuticals Teva Pharmaceutical Industries Torrent Pharma UCB Group Vaccinex Inc. Vidara Therapeutics International Voyager Therapeutics Inc
List of Organizations American Gastroenterological Association (AGA) Institute Anxiety and Depression Association of America Brain and Spinal Cord Institute Centre Hospitalier Universitaire European Huntington’s Disease Network (EHDN European Medicines Agency (EMA) FDA’s Office of Orphan Products Development FENIN, the Spanish Healthcare Technology Federation Medicaid Ministry of Health, Labor and Welfare (MHLW) Pharmaceutical Research and Manufacturers of America (PhRMA The Centers for Disease Control and Prevention (CDC) The Organisation for Economic Co-operation and Development (OECD) The Scripps Research Institute UK National Health Service (NHS) University Clinic Dusseldorf University of Auckland, New Zealand University of California at Davis US Food & Drug Administration (FDA) World Bank World Health Organisation (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Huntington’s Disease Drugs Market Forecast 2018-2028
The Alzheimer’s Disease Therapeutics and Diagnostics Market will reach $7.93bn in 2018. The Alzheimer’s Disease Therapeutics and Diagnostics Market is...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
